| Inclusion criteria | Exclusion criteria |
---|---|---|
Population | All women, whether healthy with or without a family history or increased clinical risk of BC, as well as those already diagnosed with BC. | Male |
Intervention | BRCA1/2 germline genetic testing and/or may include another genetic testing (i.e., pathogenic or likely pathogenic variants: BRCA1/2, PALB2, CHEK2, ATM, BARD1, RAD51c/d) | Somatic genetic testing, Single nucleotide polymorphism (SNP) |
Comparison | No genetic testing or alternative screening methods | Not Applicable |
Outcome | Costs per quality-adjusted life years (QALY), cost per life-years gained, and costs per number of cancer cases averted. | Cost analysis studies (e.g., with costs but no health outcomes) |
Study Design | Partial or full economic evaluation such as cost-benefit analysis (CBA), cost-utility analysis (CUA) or/and cost-effectiveness analysis (CEA) as well as cost-minimization analysis (CMA). Studies conducted in randomized controlled trials, case studies, observational studies, or model-based studies were included. | No publication of full-text articles or original data such as systematic literature reviews, commentaries (letters to the editors, editorials), abstracts, and expert review |
Language | English language | Other than the English language |
Local setting | Low- and middle-income countries | High-income countries |
Date of Publication | Until April 2023 | May 2023 onwards |